Commercialisation of bio-pharmaceutical therapies and risk management: The impact on the sustainability of markets for recombinant drugs

International Journal of Biotechnology

Volumn 6, Issue 2-3, 2004, Pages 186-201

  Wink, Rüdiger ^a  

^a LEIPZIG UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Absorptive capacity; Network externalities; Principal agent theory; Regulatory systems; Risk management; Venture capital markets

Indexed keywords

DRUG PRODUCTS; EDUCATION; ENGINEERING RESEARCH; INTELLECTUAL PROPERTY; LAWS AND LEGISLATION; PRIVATIZATION; REGULATORY COMPLIANCE;

BIOTECHNOLOGICAL KNOWLEDGE; COMMERCIALIZATION;

BIOTECHNOLOGY;

DRUG; RECOMBINANT DRUG; UNCLASSIFIED DRUG;

CAPITAL MARKET; COMMERCIALIZATION; PHARMACEUTICAL INDUSTRY; RISK ASSESSMENT; SUSTAINABILITY;

BIOTECHNOLOGY; CAPITAL; COMMERCIAL PHENOMENA; COMMERCIALIZATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; GERMANY; HUMAN; JAPAN; LAW; LEARNING; ORGANIZATION; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SCIENCE; SIDE EFFECT; THEORY; UNITED KINGDOM; UNITED STATES;

EID: 3242815531     PISSN: 09636048     EISSN: None     Source Type: Journal    
DOI: 10.1504/IJBT.2004.004809     Document Type: Review

References (44)

1. Sharp, M. and Senker, J. (1999) 'European biotechnology: learning and catching-up', in Gambardella, A. and Malerba, F. (Eds.): The Organization of Economic Innovation in Europe, Cambridge, Cambridge University Press, pp.269-302.
2. Hall, L. and Baghi-Sen, S. (2001) 'An analysis of R&D, innovation and business performance in the US biotechnology industry', International Journal of Biotechnology, Vol. 3, pp.267-286.
3. Reiss, T. (2001) 'Success factors for biotechnology: lessons from Japan, Germany and Great Britain', International Journal of Biotechnology, Vol. 3, pp.134-156.
4. Harding, R. (2003) 'The political dimension of the emergence of biotechnology in Germany and Britain', in Benzler, G. and Wink, R. (Eds.): Academia Business Links. Policy Outcomes and Lessons Learnt, Palgrave, Houndsmill.
5. Van Reenen, J. (2002) 'Economic issues for the UK biotechnology sector', New Genetics and Society, Vol. 21, pp.109-130.
6. Powell, W.W. (1996) 'Inter-organizational collaboration in the biotechnology industry', Journal of Institutional and Theoretical Economics, Vol. 152, pp.197-215.
7. McMillan, O.S., Narin, F. and Deeds, D.L. (2000) 'An analysis of the critical role of public science in innovation: the case of biotechnology', Research Policy, Vol. 29, pp.1-8.
8. Henderson, R., Orsenigo, L. and Pisano, G. (1999) 'The pharmaceutical industry and the revolution in molecular biology: interactions among scientific, institutional and organisational change', in Mowery, D. and Nelson, R. (Hrsg.): Sources of Industrial Leadership, Cambridge, Cambridge University Press, pp.43-64.
9. Cooke, P. (2003) 'Biotechnology clusters, 'Big Pharma' and the knowledge-driven economy', International Journal of Technology Management, Vol. 25.
10. Hirshleifer, J. and Riley, J.G. (1979) 'The analytics of uncertainty and risk - an expository survey', Journal of Economic Literature, Vol. 17, pp.1375-1421.
11. Chichilnisky, G. and Heal, G. (1999) 'Catastrophe futures: financial markets for unknown risk', in Chichilnisky, G. (Ed.): Markets, information, and uncertainty, Cambridge University Press, Cambridge, pp.120-140.
12. Jeng, L.A. and Wells, P.C. (2000) 'The determinants of venture capital funding. Evidence across countries', Journal of Corporate Finance, Vol. 6, pp.241-289.
13. Brav, A. and Gompers, P.A. (1997) 'Myth or reality? The long-run underperformance of initial public offerings. Evidence from venture and non-venture-capital-backed companies', Journal of Finance, Vol. 52, pp.1791-1821.
14. DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003) 'The price of innovation: new estimations of drug development costs', Journal of Health Economics, Vol. 22, pp.151-185.
15. EVCA - European Venture Capital Association (2002) Yearbook, Zaventem, EVCA.
16. Akerlof, G. (1970) 'The market for 'Lemons': qualitative uncertainty and the market mechanism', Quarterly Journal of Economics, Vol. 84, pp.488-500.
17. Grossmann, S. and Hart, O. (1983) 'An analysis of the principal-agent problem', Econometrica, Vol. 51, pp.7-45.
18. Gompers, P.A. and Lerner, J. (1996) 'The use of covenants: an empirical analysis of venture capital partnership agreements', Journal of Law and Economics, Vol. 39, pp.443-498.
19. Sahlman, W.A. (1990) 'The structure and governance of venture-capital organizations', Journal of Financial Economics, Vol. 27, pp.473-521.
20. Tirole, J. (1999) 'Incomplete contracts: Where do we stand?', Econometrica, Vol. 67, pp.741-781.
21. Cho, I-K. and Kreps, D. (1987) 'Signalling games and stable equilbria', Quarterly Journal of Economics, Vol. 102, pp.179-221.
22. Rizzello, S. (2000) Cognition and Evolution in Economics, Jena; Max-Planck-Institut zur Erforschung der Wirtschaftssysteme.
23. Wink, R. (2003) 'Transregional effects of knowledge management. Implications for policy and evaluation design', International Journal of Technology Management, Vol. 26, pp.421-438.
24. Bara, B.G. (1995) Cognitive Science. A Developmental Approach to the Simulation of the Mind, in Hove et al., LEA.
25. Anderson, J.R. (1995) Cognitive Psychology and Its Implications, 4th ed., Wiley, New York.
26. Cohen, W.M. and Levinthal, D.A. (1990) 'Absorptive capacity, a new perspective on learning and innovation', Administrative Science Quarterly, Vol. 35, pp.128-152.
27. Brown, J.S. and Duguid, P. (1991) Organizational learning and communities-of-practice: toward a unified view of working, learning, and innovation', Organization Science, Vol. 2, pp.40-57.
28. Economides, N. (1996) 'The economics of networks', International Journal of Industrial Organization, Vol. 16, pp.673-699.
29. Zucker, L., Darby, M. and Armstrong, J. (1998) 'Geographically localised knowledge: spillovers or markets?', Economic Inquiry, Vol. 36, pp.65-86.
30. Osegowitsch, T. and Madhok, A. (2001) 'Technology flows across firms and nations: an assessment of the biotechnology industry', International Journal of Biotechnology, Vol. 3, pp.217-243.
31. Thurow, L.C. (1997) 'Needed: a new system of intellectual property rights', Harvard Business Review, pp.95-103.
32. Krücken, G. (1997) Risikotransformation. Die politische Regulierung technisch-ökologischer Gefahren in der Risikogesellschaft unter besonderer Berücksichtigung von Arzneimittelregulierung und Klimapolitik, Westdeutscher Verlag, Opladen.
33. Rose-Ackermann, S., Kolstad, C.D., Ulen, T.S. and Johnson, O.S. (1990) 'Ex post liability for harm vs. ex ante safety regulation: substitutes or complements', American Economic Review, Vol. 80, pp.888-901.
34. Howells, J. (2002) 'A European innovation system in pharmaceuticals?', International Journal of Biotechnology, Vol. 4, pp.96-114.
35. Müller, C. and Fujiwara, T. (2003) 'The entrepreneurial environment for biotech start-ups in Germany and Japan', International Journal of Biotechnology, Vol. 5, pp.76-94.
36. Kong, S-K. (2001) 'The competitiveness of biotechnology in Japan', International Journal of Biotechnology, Vol. 3, pp.184-198.
37. Malinowski, M.J. (2000) 'Biotechnology in the USA: responsive regulation in the life science industry', International Journal of Biotechnology, Vol. 2, pp.16-26.
38. Sorenson, O. and Stuart, T.E. (2001) 'Syndication networks and the spatial distribution of venture capital investments', American Journal of Sociology, Vol. 106, pp.1546-1588.
39. Schertler, A. (2001) Venture Capital in Europe's Common Market: A Quantitative Description, The Kiel Institute of World Economics, Kiel.
40. Prevezer, M. and Shohet, S. (2002) 'New knowledge: production v. diffusion; the case of UK biotechnology', International Journal of Biotechnology, Vol. 4, pp.337-360.
41. Lockert, A., Murray, G. and Wright, M. (2002) 'Do UK venture capitalists still have a bias against investment in new technology firms?', Research Policy, Vol. 31, pp.1009-1030.
42. Schertler, A. (2002) Venture capitalists investment incentives under public equity schemes, The Kiel Institute of World Economics, Kiel.
43. Blum, U. and Müller, S. (2003) 'The role of intellectual property rights regimes for R&D-cooperation between industry and academia', in Benzler, G. and Wink, R. (Eds.): Academia-business linkages. Policy outcomes and lessons learnt, Houndmills, Palgrave.
44. Daem, A. (2003) 'Regulatory laws and political culture in the United States and Germany', in Abraham, J. and Lawton Smith, H. (Eds.): Regulation in the Pharmaceutical Industry, Houndmills, Palgrave.